Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.

Yasuhito Nannya, Mineo Kurokawa, Takashi Ogura, Ichiro Katayama, Akiko Moriya-Saito, Masashi Fukayama, Kiyoshi Miyagawa, Masaomi Nangaku, Yusuke Shinoda, Fumihiko Nakamura, Shunya Arai, Takashi Toya, Hiroyuki Kawashima, Yukako Murakami, Noriko Hosoya, Kenjiro Honda, Akira Honda, Aya Shinozaki-Ushiku, Akihide Yoshimi, Kazuhiro Toyama, Mizuki Ogura

Journal: Haematologica 2019;103(11):1815-1824

PMID: 29976744

Abstract

Erdheim-Chester disease is a rare histiocytosis with insufficient clinical data. To clarify the clinical features and prognostic factors of Erdheim-Chester disease, we conducted a nationwide survey to collect the detailed data of 44 patients with Erdheim-Chester disease in Japan. The median age of onset of the participants was 51 (range: 23-76) years, and the median number of involved organs per patient was 4 (range: 1-11). The existence of central nervous system disease was correlated with older age (=0.033), the presence of cardiovascular lesions (=0.015), and an increased number of involved organs (=0.0042). The median survival from the onset was 10.4 years, and >3.0 mg/dL C-reactive protein level at onset was associated with worse outcome (median survival, 14.6 7.4 years; =0.0016). In a multivariate analysis, age >60 years (hazard ratio, 25.9; 95% confidence interval, 2.82-237; =0.0040) and the presence of digestive organ involvement (hazard ratio, 4.74; 95% confidence interval, 1.05-21.4; =0.043) were correlated with worse survival. Fourteen patients had available histological samples of Erdheim- Chester disease lesions. V600E mutation was detected in 11 patients (78%) by Sanger sequencing. A correlation between mutation status and clinical factors was not observed. Our study revealed that age and digestive organ involvement influence the outcome of Erdheim-Chester disease patients, and an inflammatory marker, such as C-reactive protein, might reflect the activity of this inflammatory myeloid neoplasm.

Copyright© 2018 Ferrata Storti Foundation.

Address: Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo.; Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital.; Department of Pathology, Graduate School of Medicine, The University of Tokyo.; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine.; Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo.; Department of Dermatology, Osaka University Graduate School of Medicine.; Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences.; Department of Rehabilitation Medicine Graduate School of Medicine, The University of Tokyo.; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi.; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.; Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.